In people with preexisting conditions like chronic kidney disease or liver cirrhosis, high-dose IV infusion may place additional stress on these organs
Understanding which patients are candidates for GLP-1RAs treatment will be key, according to Lorenzo Leggio, MD, PhD, clinical director of the National Institute on Drug Abuse
Breaks make sense for users experiencing treatment plateau where benefits cease increasing despite continued application suggesting diminishing returns from ongoing use, comfortable with some benefit decline during off periods accepting fluctuation in skin quality, budget-conscious seeking to minimize annual treatment costs through intermittent purchasing, philosophically preferring avoiding indefinite dependency on any skincare product, planning life changes incompatible with consistent application (extended travel, relocation, financial shifts), and wanting to assess whether improvements prove durable or require continuous maintenance before committing to indefinite treatment
A beneficiary with a BMI of 32 and uncontrolled hypertension, or a BMI of 28 with pre-diabetes and a prior stroke, previously had no straightforward path to GLP-1 coverage